Sanan Optoelectronics LED Enables Display Trends in Consumer Electronics at CES 2019
Top Manufacturers to Unveil Latest Products with Company’s Mini LED & Advanced Micro LED Chips
XIAMEN, China, Jan. 10, 2019 (GLOBE NEWSWIRE) -- SANAN OPTOELECTRONICS CO., LTD. (Sanan Optoelectronics), the world’s leading light-emitting diode (LED) epitaxial wafer and chip manufacturer, announced that several panel manufacturers for TVs, digital displays, smartphones, smart watches, augmented / virtual reality (AR/VR) goggles, and gaming notebooks have unveiled new products this week using the company’s latest Mini LED and advanced Micro LED chips at the 2019 Consumer Electronics Show (CES). Since the technology debuted at CES in 2017, the company has led the industry in large-scale production of RGB Mini LEDs, and has complimented its portfolio with R&D advancements and capacity investments for Micro LED, including 27 applied patents and key partnerships.
Given the maturity of Mini LED technology, display panel manufacturers are widely implementing across a broad range of consumer applications, including for cinema screens, and soon also for automotive. Mini LEDs, with its compact unit size between 100 to 200 micrometers, allow for high density backlight designs with local dimming capabilities. It helps create ultra-thin, ultra-compact designs with stylistic features such as for notch and curved form-factors. As a display technology, it provides superior energy efficiency with ultra-high brightness, high dynamic range (HDR), with higher color saturation, contrast and resolution compared to the traditional liquid crystal display (LCD) approach. Micro LED is poised to be the revolutionary next-generation technology, which offer significant advances in image quality through individually driven self-emitting pixels and in even more miniaturized form-factors.
“We see tremendous growth in the Mini LED market, and are delighted to see its increased adoption from among the product launches here at CES”, says Simon Lin, CEO of Sanan Optoelectronics. “The industry is certainly taking full advantage of the key benefits that Mini LEDs bring, namely enhanced power savings, and higher performance. Given the success of our core business in LED chips combined with our manufacturing infrastructure and cost competitiveness through economies of scale, we have been able to overcome the high barrier of entry for the Mini LED market. While we are fully committed to drive innovation further for this technology and are well positioned to support the market’s high volume demand, we are also ramping up R&D and scaling up capacity for Micro LED production to meet the demands of the next wave of innovative LED displays”.
The company offers a family of RGB display and backlight Mini LEDs with various element sizes, dimensions, and light output power (LOP) ratings, ideal for these emerging applications and market trends, with high volume production capacity. Customized form-factors and solutions are also available. The company has also expanded its manufacturing capabilities and facilities for Micro LED production. Learn more about Sanan Optoelectronics’ LED portfolio. Visit www.sanan-e.com/en.
About Sanan Optoelectronics
Founded in November 2000, Sanan Optoelectronics Co., Ltd. is engaged in the R&D, large-scale production and marketing of full-color, ultra high-brightness light-emitting diode (LED) epitaxial wafers and chips, as well as compound solar cells, based on gallium nitride (GaN) and gallium arsenide (GaAs) compound semiconductors. Headquartered in Xiamen City in the Fujian Province of China, the company is publicly traded and is listed under the Shanghai Stock Exchange (SSE: 600703). Certified to the ISO9001 international quality standard and ISO14001 environmental management standard, the company was the earliest established LED manufacturer in China, and has a technical workforce of over 10,000 employees globally. www.sanan-e.com/en
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
WillScot to Participate at the Barclays Industrial Select Conference16.1.2019 21:00 | Pressemelding
BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”)(NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Barclays Industrial Select Conference at the Loews Miami Beach Hotel in Miami, Florida, on Wednesday, Feb. 20, 2019. The presentation will take place at 10:20 a.m. EST. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the WillScot family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for t
CCI has been retained by Waterloo Brewing to obtain Cannabis Licence16.1.2019 16:00 | Pressemelding
TORONTO, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cannabis Compliance Inc., (CCI) of Toronto, Ontario is pleased to announce they have partnered with Waterloo Brewing to help them obtain their Research and standard Processing Licence to develop cannabis-infused beverages. “CCI is working with Waterloo Brewing on the early stages of the application process and we are confident that we will help them achieve their desired licenses in time to be an active player in this growing sector of the cannabis industry”, said Brian Wagner, CEO and Founder, Cannabis Compliance Inc. “We are here to guide our clients through the early stages of the licensing process and for the many Health Canada requirements thereafter.” CCI offers end to end business solutions for cannabis companies large and small. Our team brings with them years of experience in the quality, regulatory, security and cultivation sectors, and supports manufacturers and retailers through regulatory challenges. As the world’s largest and mos
Aryaka Announces Expansion of Senior Leadership Team with New Chief Revenue Officer, Chief Transformation Officer and Chief Marketing Officer16.1.2019 15:00 | Pressemelding
Karen Freitag, Michelle Owczarzak, & Shashi Kiran join Aryaka to address significant growth and assist global enterprises in adopting managed connectivity as-a-service SAN MATEO, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aryaka®, announced today the appointment of several new executive hires to the company’s leadership team, including Karen Freitag (Chief Revenue Officer), Michelle Owczarzak (Chief Transformation Officer), and Shashi Kiran (Chief Marketing Officer). “Connectivity is the lifeblood of the global enterprise and Aryaka is the industry benchmark for secure managed connectivity worldwide. We are excited to have experienced industry veterans join our robust executive leadership team and continue to help build upon the immense success and growth that Aryaka has seen in recent years,” said Matt Carter, CEO of Aryaka. “As our customers expand globally, embrace SD-WAN, or move to the cloud, we’re becoming the de facto choice for their needs to make this happen better, faster, che
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors16.1.2019 07:00 | Pressemelding
Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic. ADCT-601 is an ADC composed of a humanized monoclonal antibody against human AXL, conjugated using GlycoConnect™ site specific conjugation technology to a pyrrolobenzodiazepine (PBD) dimer toxin. In preclinical studies, ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in multiple cancer-derived models with different levels of AXL expression, and was stable and well tolerated
GSA Europe’s Managing Director Elected Co-lead of CEN’s TC456 Committee15.1.2019 21:12 | Pressemelding
SAN GWANN, Malta, Jan. 15, 2019 (GLOBE NEWSWIRE) -- GSA Europe’s Managing Director Mark Pace has been elected by the Comité Européen de Normalisation (CEN) to lead the creation of a European Union online gaming reporting standard. CEN has established Technical Committee 456 to create this standard in support of online gambling supervision. GSA Europe joined Technical Committee 456 as a Liaison Organization in 2017. The Technical Committee’s mandate from the European Commission is directly aligned with work that GSA Europe has already started, namely, to create a single standard set of data elements and single standard way in which data is provided by online gambling providers to EU Member State regulatory authorities. In addition to joining and now leading the Technical Committee’s work, GSA Europe also donated their draft Regulatory Data Set and Regulatory Reporting Interface to CEN seeking to help jump-start the Committee’s work. “Joining CEN’s TC456 as a Liaison Organization, and no
Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study15.1.2019 15:00 | Pressemelding
OTTAWA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Three days after inoculation intraperitoneal treatment was started with OB-002O, a murine anti-PD-1 antibody, OB-002 + anti-PD-1, or saline placebo. Treatment was given daily or every third day. Treatment with OB-0020 alone led to statistically significant delayed tumor growth at multiple time-points. An even more profound effect on the decrease in mean tumor volume was observed in combination cohort where animals received both, OB-0020 and the anti-PD-1 antibody (p>0.05). “There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist